Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17β-estradiol and norethindrone acetate

2001 ◽  
Vol 184 (6) ◽  
pp. 1131-1138 ◽  
Author(s):  
Inga-Stina Ödmark ◽  
Björn Jonsson ◽  
Torbjörn Bäckström
Keyword(s):  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Medroxyprogesterone Acetate ◽  
Hormone Replacement ◽  
17Β Estradiol ◽  
Conjugated Estrogen ◽  
Norethindrone Acetate

No increased risk of endometrial hyperplasia with fixed long-cycle hormone replacement therapy after two years

2002 ◽  
Vol 8 (4) ◽  
pp. 155-156
Author(s):  
Risto Erkkola ◽  
Ulpu Kumento ◽  
Sirpa Lehmuskoski ◽  
Leena Mattila ◽  
Mika Mustonen
Keyword(s):  
Clinical Trial ◽  
Hormone Replacement Therapy ◽  
Replacement Therapy ◽  
Postmenopausal Women ◽  
Medroxyprogesterone Acetate ◽  
Endometrial Hyperplasia ◽  
Hormone Replacement ◽  
Long Cycle ◽  
Increased Risk

The appropriate dose of progestogen during long-cycle hormone replacement is still under debate. We present preliminary two-year results from an open five-year clinical trial of 132 postmenopausal women. All subjects had long-cycle HRT consisting of 70 days 2 mg oestradiol valerate (E2V), followed by 14 days 2 mg E2V plus 20 mg medroxyprogesterone acetate, and a seven-day hormone-free period. No endometrial samples with hyperplasia or indicative of malignancy were found at 24 months.

Sign in / Sign up

Export Citation Format

Share Document